Last Friday, Frazier Life Sciences hit the Nasdaq with its second biotech-focused SPAC. TCGX is already on the hunt for ...
Eli Lilly has formed a partnership with Hong Kong's Metis TechBio worth up to $1.1 billion, gaining access to an AI drug ...
Gilead Sciences has notched a phase 2 win in ulcerative colitis (UC), with its once-daily pill emvistegrast outperforming ...
Enlivex is laying off 60% of its workforce, ending preclinical R&D and trimming its top execs’ salaries as the Israeli ...
Germany’s Merck KGaA has picked up Silence Therapeutics to the tune of $1.3 billion in the wake of the British biotech’s mid-stage success for its challenger to Takeda’s Mimrylo. The all-cash deal ...
Disc’s phase 3 trial provides a clearer link between the biomarker, whole-blood metal-free protoporphyrin IX (PPIX), and ...
The pharmaceutical industry has traditionally viewed drug discovery and clinical development as separate stages of the R&D ...
Paradromics has announced a new collaboration with Siemens Healthineers to construct an advanced multimodal imaging platform ...
The fourth Riyadh Global Medical Biotechnology Summit (RGMBS) closed on September 16 with 46 agreements signed. Disclosed ...
A year after their first antibody-drug conjugate (ADC) team-up, Roche has returned to Hansoh Pharmaceutical for a mammoth $15 billion biobucks pact.
AbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial. Skyrizi is a ...
Nouscom has reeled in 120 million euros ($135 million) in series D funds to take a cancer-preventing vaccine through a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results